Lispro mix 75/25 + Glargine

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Type 2 Diabetes

Conditions

Type 2 Diabetes

Trial Timeline

May 1, 2003 → Dec 1, 2004

About Lispro mix 75/25 + Glargine

Lispro mix 75/25 + Glargine is a approved stage product being developed by Eli Lilly for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT00551538. Target conditions include Type 2 Diabetes.

What happened to similar drugs?

20 of 20 similar drugs in Type 2 Diabetes were approved

Approved (20) Terminated (1) Active (0)

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00551538ApprovedCompleted